• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

79.94 -2.40 (-2.91%)
Streaming Delayed Price Updated: 1:40 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 296,144
Open 81.05
Bid (Size) 79.82 (200)
Ask (Size) 80.05 (300)
Prev. Close 82.34
Today's Range 79.79 - 82.14
52wk Range 33.70 - 96.54
Shares Outstanding 62,107,572
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
January 07, 2026
Via ACCESS Newswire
News headline image
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
January 05, 2026
From Takeda Pharmaceutical Company Limited
Via Business Wire

Performance

YTD
-8.3%
-8.3%
1 Month
-11.4%
-11.4%
3 Month
+22.4%
+22.4%
6 Month
+52.9%
+52.9%
1 Year
+107.9%
+107.9%

More News

Read More
News headline image
Protagonist (PTGX) Earnings Call Transcript ↗
November 27, 2025
Via The Motley Fool
Topics Earnings
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗
October 14, 2025
Via Stocktwits
News headline image
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
November 27, 2025
Via ACCESS Newswire
News headline image
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 06, 2025
Via ACCESS Newswire
News headline image
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
November 03, 2025
Via ACCESS Newswire
News headline image
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
October 28, 2025
Via Benzinga
News headline image
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
October 27, 2025
Via ACCESS Newswire
News headline image
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗
October 23, 2025
Via The Motley Fool
Topics Energy
News headline image
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗
October 23, 2025
Via The Motley Fool
News headline image
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗
October 21, 2025
Via The Motley Fool
Topics Regulatory Compliance
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
October 20, 2025
Via AB Newswire
News headline image
2 Top Dividend Kings Every Income Investor Should Own ↗
October 20, 2025
Via The Motley Fool
Topics Bonds
News headline image
Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗
October 18, 2025
Via MarketBeat
News headline image
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗
October 14, 2025
Via Benzinga
News headline image
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗
October 14, 2025
Via Stocktwits
Topics Government World Trade
News headline image
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗
October 13, 2025
Via Benzinga
News headline image
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗
October 13, 2025
Via Benzinga
News headline image
Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗
October 13, 2025
Via Chartmill
Topics Artificial Intelligence Government World Trade
News headline image
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today ↗
October 10, 2025
Via The Motley Fool
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
October 10, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
October 10, 2025
Via Benzinga
News headline image
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗
October 10, 2025
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Friday? ↗
October 10, 2025
Via Chartmill

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
The current price of Protagonist Therapeutics, Inc. - Common Stock is 79.94
When was Protagonist Therapeutics, Inc. - Common Stock last traded?
The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 01/08/26 01:40 PM ET
What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 4.96B
How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
Protagonist Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap